Benitec Biopharma to Participate in Upcoming Investor Conferences in December

Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference platform, has announced their participation in two upcoming investor conferences in December 2024.

The company will participate in the Piper Sandler Annual Healthcare Conference on December 4, 2024, at 12:00 PM EST in New York, featuring a fireside discussion and one-on-one meetings. Additionally, they will attend the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, from 9:50-10:40 AM EST in New York, participating in a panel discussion and one-on-one meetings.

News Market Reaction – BNTC

-2.96%

1 alert

-2.96% News Effect

On the day this news was published, BNTC declined 2.96%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences.

Piper Sandler Annual Healthcare Conference
Date: December 4, 2024
Time of Fireside Discussion: 12:00 PM EST
Location: New York, NY
Format: Fireside Discussion & 1x1 Meetings

The Benitec presentation will also be available via live webcast here.

Oppenheimer Movers in Rare Disease Summit
Date: December 12, 2024
Time of Fireside Chat: 9:50-10:40 AM EST
Location: New York, NY
Format: Panel discussion & 1x1 Meetings

Please contact your conference representative to schedule a 1x1 meeting with Benitec management.

About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Investor Relations Contact:

Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com

FAQ

What investor conferences will Benitec Biopharma (BNTC) attend in December 2024?

Benitec Biopharma will attend the Piper Sandler Annual Healthcare Conference on December 4 and the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, both in New York.

When is Benitec Biopharma's (BNTC) presentation at the Piper Sandler Healthcare Conference?

Benitec Biopharma's fireside discussion at the Piper Sandler Healthcare Conference is scheduled for December 4, 2024, at 12:00 PM EST.

What type of technology platform does Benitec Biopharma (BNTC) use?

Benitec Biopharma uses a proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform for developing novel genetic medicines.